Carboxyesterase biocatalysts

Patent metadata

Field	Value
Publication number	US-11535833-B2
Application number	US-201816771279-A
Country	US
Kind code	B2
Filing date	Dec 13, 2018
Priority date	Dec 13, 2017
Publication date	Dec 27, 2022
Grant date	Dec 27, 2022

Abstract

The present disclosure provides engineered carboxyesterase enzymes that have the ability to catalyze amide bond formation. Also provided are polynucleotides encoding the carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes to make commercially valuable amides. Also provided are amides that are made using the engineered carboxyesterase enzymes.

First claim

We claim:

1. A carboxyesterase polypeptide having carboxyesterase activity and comprising an amino acid sequence that is at least 93%, or more identical to the amino acid sequence set forth in SEQ ID NO: 4, wherein the residue corresponding to X198 in SEQ ID NO: 4 is a leucine (L) residue.

2. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further comprises a residue difference as compared to the amino acid sequence set forth in SEQ ID NO: 4 in at least one residue position selected from the group consisting of: X27, X30, X35, X37, X57, X75, X103, X185, X207, X208, X271, X286, and X296.

3. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further comprises
an aliphatic residue or an aromatic residue at the residue corresponding to X103.

4. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further includes at least one feature selected from the group consisting of: X27 is P; X30 is I, L, or V; X35 is H; X37 is I, L, T, or V; X57 is M; X75 is R; X103 is F, M, or W; X185 is F, I, or M; X207 is E; X208 is R, L, or H; X271 is D; X286 is M, V, or G; and X296 is V, L, or R.

5. The carboxyesterase polypeptide of claim 1 , wherein the carboxyesterase polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4.

6. A process for preparing an amide, wherein components are combined containing:
(a) an ester substrate of the form R1-COOR2, wherein R1 is chosen from: an sp3 carbon with 0 to 3 alkyl substituents; and an aromatic ring, and R2 is chosen from: a methyl group; an ethyl group; and 1-6 carbon alkyl chains;
(b) an amine substrate;
(c) a carboxyesterase polypeptide comprising an amino acid sequence that is at least 93% identical to the amino acid sequence set forth in SEQ ID NO: 4, wherein the residue corresponding to X198 in SEQ ID NO: 4 is a L residue; and
(d) a solvent.

7. The process of claim 6 , wherein the carboxyesterase polypeptide in step (c) is prepared in the presence of a salt.

8. The process of claim 7 , wherein the salt is chosen from: sodium sulfate; potassium sulfate; lithium sulfate; sodium phosphate; and potassium phosphate.

9. The process of claim 6 , wherein the solvent is an organic solvent chosen from: toluene; 2-methyltetrahydrofuran; tetrahydrofuran;
dimethylacetamide; methyl isobutyl ketone (MIBK); dichloromethane; tert-butyl methyl ether;
cyclopentyl methyl ether; methyl cyclohexane; dichloromethane; acetonitrile; methyl ethyl ketone; isopropyl acetate; ethanol; isopropanol; ethyl acetate; heptane; xathane; and 2-methyltetrahydrofuran (2-Me-THF); and water.

10. The process of claim 9 , wherein the organic solvent contains up to 3 molar equivalents of water relative to the ester substrate in an amount of from about 0.5% (vol/vol) to about 3% (vol/vol).

11. The process of claim 6 , wherein the ester substrate is ethyl oxazole 5-carboxylate that has the formula:

the amine substrate is 1-isopropy 1piperazine that has the formula:

and the amide is (4-isopropylpiperazin-1-yl)(oxazol-5y1)methanone that has the formula:

12. The process of claim 6 , wherein the ester substrate is ethyl oxazole-5-carboxylate that has the formula:

the amine substrate is cis-2,6-dimethylmorpholine that has the formula:

and the amide is ((2S,6R)-2,6-dimethylmorpholino)(oxazol-5-yl)methanone that has the formula:

13. The process of claim 6 , wherein the reaction comprises: about 40 g/L ethyl oxazole-5-carboxylate, about 44 g/L 1-isopropylpiperazine, and about 20 g/L of a carboxyesterase polypeptide comprises the amino acid sequence set forth in the SEQ ID NO: 4, wherein the carboxyesterase polypeptide is prepared in the presence of sodium sulfate and run in the presence of from about 10 g/L to about 20 g/L water in MIBK.

14. The carboxyesterase polypeptide of claim 3 , wherein X103 is an aromatic residue.

15. The carboxyesterase polypeptide of claim 14 , wherein X103 is a tryptophan (W) residue.

16. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further comprises a non-polar residue, an aliphatic residue, or an aromatic residue at the residue corresponding to X185.

17. The carboxyesterase polypeptide of claim 16 , wherein X185 is an aromatic residue.

18. The carboxyesterase polypeptide of claim 17 , wherein X185 is a phenylalanine (F) residue.

Assignees

• Glaxosmithkline Ip Dev Ltd

Inventors

• Brown Kristin K
• Dorr Brent M
• Fuerst Douglas E
• Honicker Katherine Joyce
• Jordan Lydia Sanchez
• Morrison James Patrick
• Plotnikov Nikolay V
• Schober Markus
• Voladri Rama

Classifications

• C12Y301/01001

  Carboxylesterase (3.1.1.1) · CPC title

• C12P17/16

  containing two or more hetero rings {(thiamine open chain analogs C12P17/167, i.e. not condensed among themselves or through a common carbocyclic ring system)} · CPC title

• C12P17/165

  Heterorings having nitrogen atoms as the only ring heteroatoms · CPC title

• C12N9/18 Primary

  Carboxylic ester hydrolases {(3.1.1)} · CPC title